3 Cardiac glycosides.
Beta-adrenoceptor antagonists

Mode of action
Beta-adrenoceptor antagonists occupy the beta-receptors and prevent the action of endogenous catecholamines. The drugs associated with the greatest toxicity are non-selective with membrane stabilising effects: for example, propranolol and those with class III arrhythmia activity such as sotalol. 1 
Clinical features
Most patients who have taken a large dose of a beta-blocker will demonstrate bradycardia and hypotension. With very large doses there will be coma, convulsions and profound hypotension. A variety of cardiac dysrhythmias and ECG abnormalities are described. The more serious of these can result in cardiorespiratory arrest. 2, 3 These include:
heart block intraventricular conduction defects ST segment elevation absent P waves, and ventricular fibrillation or asystole.
Management
Gastric lavage and activated charcoal (50-100 g) may be considered if a large overdose has been taken within one hour of presentation, although evidence of efficacy for both is poor. 
Calcium channel blocking drugs
Mode of action
Calcium channel blocking drugs act by preventing the opening of voltage-gated calcium L channels in cardiac and smooth muscle cells. This results in vasodilation, negative inotropic activity and delay in cardiac conduction. Serious problems relate to effects on the heart, so diltiazem and verapamil, which have major effects on cardiac contraction and conduction, are more likely to cause serious toxicity. Sustained-release preparations, which are widely available, produce delayed and prolonged toxicity. 3, 4 Clinical features Vasodilation, myocardial depression and heart block combine to cause profound hypotension in severe overdoses. These effects can be delayed for up to 18-24 hours if a controlled-release preparation has been ingested. Sinus bradycardia is common but in severe overdosage patients can develop junctional and idioventricular rhythms which can result in asystole. Several factors are associated with a poor prognosis, including:
old age history of cardiovascular disease co-ingestion of beta-adrenoceptor antagonists or cardiac glycosides metabolic acidosis, and the presence of heart block or ventricular arrhythmia. Gastrointestinal symptoms are common (eg nausea, vomiting and paralytic ileus). Other features include hyperglycaemia, hypoglycaemia, seizures and non-cardiogenic pulmonary oedema. [2] [3] [4] 
Management
Full resuscitation facilities should be available for all but the most trivial of overdoses. The advice given for overdoses with beta-adrenoceptor antagonists relating to gastric lavage and use of atropine also apply to calcium channel blockers. Repeated doses of activated charcoal and whole bowel irrigation with polyethylene glycol electrolyte solution for slow-release preparations have been advocated, but their value is uncertain.
Intravenous calcium is frequently used as an initial treatment in patients who have taken verapamil or diltiazem and demonstrate evidence of heart block. It is not universally effective and the dosage regimens vary widely. A commonly recommended regimen is an initial dose of 5-10 ml of 10% calcium chloride solution (0.2 ml/kg in children) infused at a rate no faster than 1-2 ml/min. This can be followed by further doses every 3-5 min if there is no response. Large doses (up to 10 g initially, 30 g in total) have been used successfully without evidence of calcium toxicity. If there is an initial response, a continuous infusion of 1-10 ml/hr (0.03-1.0 ml/kg/hr in children) of 10% calcium chloride can be given. Careful monitoring of the cardiac rhythm and serum calcium is required, but it is important to remember that a degree of hypercalcaemia is necessary for effective treatment. [2] [3] [4] Hypotension is usually best treated by volume expansion and occasionally with pressor agents. Glucagon is sometimes used to reverse myocardial depression, and isoprenaline and noradrenaline are given to increase heart rate and blood pressure. In resistant cases, ventricular pacing may be required. There is recent evidence that insulin-dextrose infusion may be useful in reversing hypotension, bradycardia and metabolic acidosis in patients unresponsive to conventional treatment. 5 
Cardiac glycosides
Mode of action
Digoxin (and other cardiac glycosides) inhibit the Na + /K + ATPase transport mechanism in myocardial and cardiac conducting tissue. This results in an increase in intracellular sodium, which in turn reduces the release of calcium from the cell by a Na + /Ca 2+ exchange mechanism. Intracellular concentrations of calcium subsequently rise. The overall haemodynamic effects are: a relatively weak inotropic effect delay in conduction at the atrioventricular (AV) node and His-Purkinje system, and increased automaticity and excitability. Binding to the Na + /K + ATPase transport system is inhibited by high levels of potassium and magnesium. As a result, hypokalaemia and hypomagnesaemia increase digoxin toxicity and increased concentrations are protective. Drugs will also increase toxicity if they: retard conduction at the AV node (verapamil, beta-adrenoceptor antagonists)
reduce serum potassium and/or magnesium (diuretics), or decrease the clearance of digoxin (quinidine, verapamil amiodarone). Increased sensitivity to digoxin has also been described in cor pulmonale, hypothyroidism and chronic hypoxaemia. 6 
Clinical features
Major adverse effects of the cardiac glycosides relate almost exclusively to their effects on cardiac conduction, although nausea, vomiting, diarrhoea and visual disturbances can be troublesome. Important bradyarrhythmias include second-and third-degree heart block and atrial fibrillation with a slow ventricular response. Relatively slow junctional or atrial tachycardias also occur, while ventricular tachycardias and fibrillation can occur as a result of increased automaticity and late after depolarisations. 7 
Management
All patients require an urgent ECG, electrolyte estimation and serum digoxin measurement at least six hours after the overdose. Hypokalaemia and hypomagnesaemia should be corrected, but no attempt made to lower the serum potassium, as this is an indicator of the severity of digoxin poisoning and can be used to determine whether antibody treatment is required.
Digoxin antibodies are a specific treatment of digoxin overdose. They are indicated for patients with life-threatening dysrhythmias (ventricular tachycardia, ventricular fibrillation and complete heart block) and/or a serum potassium greater than 6 mmol/l and/or serum digoxin level greater than 10 mmol/l six hours after overdose. Patients with underlying cardiac disease who have been receiving maintenance digoxin may be considered for antibody therapy although they may not strictly meet the above criteria. Digoxin Fab bind rapidly to digoxin, and the complex is renally excreted (elimination half-life 12-24 hours) in those with normal renal function. As digoxin Fab binds to digoxin in a 1:1 ratio, the total dose required can be calculated in one of two ways:
from the number of tablets ingested (if known): 3 mg digoxin requires 5 40 mg vials of Fab (40 mg vial binds 0.6 mg digoxin), or using serum concentration and estimates of the apparent volume of distribution. Alternatively, the dose can be titrated against the clinical response, especially when heart block and hyperkalaemia are the presenting features.
In general, antiarrhythmic drugs are problematical and should be avoided if possible. Pacing may occasionally be required if there is a delay in administering the digoxin antibodies. Atropine can be given to increase heart rate, and magnesium has been shown to be useful for some tachyarrhythmias. Class IB antiarrhythmic drugs are preferred to class IA as they do not impair AV conduction. 7, 8 
